Tags

Type your tag names separated by a space and hit enter

Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
Clin Appl Thromb Hemost. 2008 Jul; 14(3):319-24.CA

Abstract

Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (beta = .455) and HDL-cholesterol (beta = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content.

Authors+Show Affiliations

Hemostasis and Thrombosis Laboratory, Hospital of Infectious diseases, F J Muniz, Argentina. gabriela@inkmedia.com.arNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18160600

Citation

de Larrañaga, Gabriela, et al. "Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol. 14, no. 3, 2008, pp. 319-24.
de Larrañaga G, Wingeyer SP, Graffigna M, et al. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin Appl Thromb Hemost. 2008;14(3):319-24.
de Larrañaga, G., Wingeyer, S. P., Graffigna, M., Belli, S., Bendezú, K., Alvarez, S., Levalle, O., & Fainboim, H. (2008). Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 14(3), 319-24.
de Larrañaga G, et al. Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome. Clin Appl Thromb Hemost. 2008;14(3):319-24. PubMed PMID: 18160600.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. AU - de Larrañaga,Gabriela, AU - Wingeyer,Silvia Perés, AU - Graffigna,Mabel, AU - Belli,Susana, AU - Bendezú,Karla, AU - Alvarez,Silvia, AU - Levalle,Oscar, AU - Fainboim,Hugo, Y1 - 2007/12/26/ PY - 2007/12/28/pubmed PY - 2008/9/4/medline PY - 2007/12/28/entrez SP - 319 EP - 24 JF - Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis JO - Clin Appl Thromb Hemost VL - 14 IS - 3 N2 - Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (beta = .455) and HDL-cholesterol (beta = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content. SN - 1076-0296 UR - https://www.unboundmedicine.com/medline/citation/18160600/Plasma_plasminogen_activator_inhibitor_1_levels_and_nonalcoholic_fatty_liver_in_individuals_with_features_of_metabolic_syndrome_ L2 - https://journals.sagepub.com/doi/10.1177/1076029607304094?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -